Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TP chemotherapy plus cetuximab beta and tislelizumab induction for locally advanced hypopharyngeal cancer
ChiCTR2500106133Phase 2Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Jul 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, cetuximab, docetaxel and cisplatin in squamous cell carcinoma of the hypopharynx, sponsored by Sichuan Cancer Hospital. Primary endpoint: Objective Response Rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
tislelizumabcetuximabdocetaxelcisplatin
03
Conditions
squamous cell carcinoma of the hypopharynx
Beyond the preview
Go deeper on ChiCTR2500106133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106133.